BioProspect cops Euro setback
Friday, 01 July, 2005
Brisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths.
Neudorff cited concerns about the estimated cost of manufacturing and registering a formulated Qcide product for Germany and Europe.
Only three months ago, BioProspect received a similar knockback from another potential partner, Sumitomo Australia. At the time, Bioprospect said the Neudorff trials were "progressing very well".
In the wake of thefailed deal, the company said it was continuing with other confidential evaluation agreements in Australia and the US for the consumer goods and animal markets.
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
